Glial neurotrophic factor as a predictor of resistance to the treatment of patients with ankylosing spondylitis

Glial neurotrophic factor (GDNF) is a promising marker of therapeutic efficacy in ankylosing spondylitis, however, its role is poorly understood. Aim: to evaluate the role of GDNF as a predictor of resistance to therapy in ankylosing spondylitis. Materials and methods. The results of treatment of 21 patients with ankylosing spondylitis with a reduced (less than 3.0 pg/ml) and 22 patients with a normal (3 pg/ml and above) level of GDNF in blood plasma were compared. Results. The specific gravity of ASAS20 responders among patients with normal GDNF levels was significantly higher: 45.5% versus 14.3%, (p<0.05). In ASAS20 non-responders, the mean GDNF level was significantly lower compared to responders: 2.915±1.466 pg/ml versus 4.395±2.298 pg/ml (p<0.01). Patients with normal GDNF content showed significantly better dynamics of neuropathic pain indicators during therapy compared to patients with reduced GDNF content according to LANNS questionnaires: 25.0±31.0% versus 1.6±3.7% (p<0, 05) and DN4: 1.5±4.9% versus 28.8±36.0% (p<0.01), respectively. Patients with normal GDNF content had better dynamics of recovery of functional ability according to BASMI: 24.5±25.1% vs. 13.3±23.7% (p<0.05), respectively. They also showed better indicators of growth in the quality of life in the course of therapy according to ASQoL: 25.0±14.6% versus 14.7±9.0% (p<0.05) and a decrease in manifestations of reactive anxiety: 20.8±20.6% versus 5.5±7.0% (p<0.05), respectively. They also showed better indicators of growth in the quality of life in the course of therapy according to ASQoL: 25.0±14.6% vs 14.7±9.0% (p<0.05) and a decrease in manifestations of reactive anxiety: 20.8±20.6% vs 5.5±7.0% (p<0.05), respectively. Patients with normal levels of GDNF in blood plasma had slightly better health, general quality of life, and depression than patients with reduced levels of GDNF. Conclusions. A reduced level of GDNF in the blood plasma (less than 3 pg/ml) is associated with lover treatment efficacy regarding ASAS20 criteria, lower positive dynamic of neuropathic pain markers, functional capacity, quality of life and mental sphere, which allows to consider a reduced level of GDNF as an additional predictor of therapeutic resistance in patients with ankylosing spondylitis.

References

1. Timmis A., Townsend N., Gale C. et al. (2017) European Society of Cardiology: Cardiovascular Disease Statistics. Eur. Heart J., 39(7): 508–579. doi: 10.1093/eurheartj/ehx628.
2. Stewart S., Ahamed Y., Wiley J.F. et al. (2016) Seasonal variations in cardiovascularrelated mortality but not hospitalization are modulated by temperature and not climate type: a systematic review and meta-analysis of 4.5 million events in 26 countries. Circul., 134: A16759–A16759.
3. Eaton S.B., Konner M. (1985) Paleolithic nutrition. A consideration of its nature and current implications. N. Engl. J. Med., 312(5): 283–289. doi: 10.1056/NEJM198501313120505.
4. Borghi C., Tsioufis K., Agabiti-Rosei E. et al. (2020) Nutraceuticals and blood pressure control: a European Society of Hypertension position document. J. Hypertens., 38(5): 799–812. doi: 10.1097/HJH.0000000000002353.
5. Umesawa M., Iso H., Date C. et al. (2008) Relations between dietary sodium and potassium intakes and mortality from cardiovascular disease: the Japan Collaborative Cohort Study for Evaluation of Cancer Risks. Am. J. Clin. Nutr., 88(1): 195–202. doi: 10.1093/ajcn/88.1.195.
6. Seth A., Mossavar-Rahmani Y., Kamensky V. et al. (2014) Potassium intake and risk of stroke in women with hypertension and nonhypertension in the Women’s Health Initiative. Stroke, 45(10): 2874–2880. doi: 10.1161/STROKEAHA.114.006046.
7. Aburto N.J., Hanson S., Gutierrez H. et al. (2013) Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ, 346: f1378. doi: 10.1136/bmj.f1378.
8. Wang A., Cao S., Tian X. et al. (2022) Lower Serum Potassium Levels at Admission are Associated with the Risk of Recurrent Stroke in Patients with Acute Ischemic Stroke or Transient Ischemic Attack. Cerebrovasc. Dis., 51(3): 304–312. doi: 10.1159/000520052.
9. Guasch-Ferré M., Bulló M., Estruch R. et al. (2014) Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J. Nutr., 144(1): 55–60. doi: 10.3945/jn.113.183012.
10. Sheu J.R., Hsiao G., Shen M.Y. et al. (2002) Mechanisms involved in the antiplatelet activity of magnesium in human platelets. Br. J. Haematol., 119(4): 1033–1041.
11. Mohammadifard N., Gotay C., Humphries K.H. et al. (2019) Electrolyte minerals intake and cardiovascular health. Crit. Rev. Food Sci. Nutr., 59(15): 2375–2385. doi: 10.1080/10408398.2018.1453474.
12. Houston M. (2011) The role of magnesium in hypertension and cardiovascular disease. J. Clin. Hypertens., 13: 843–847.
13. Kass L., Weekes J., Carpenter L. (2012) Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur. J. Clin. Nutr., 66: 411–418. doi: 10.1038/ejcn.2012.4.
14. Pickering R.T., Bradlee M.L., Singer M.R. et al. (2021) Higher Intakes of Potassium and Magnesium, but Not Lower Sodium, Reduce Cardiovascular Risk in the Framingham Offspring Study. Nutrients., 13(1): 269. doi: 10.3390/nu13010269.
15. Woods K.L., Fletcher S., Roffe C. et al. (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet, 339: 1553–1558. doi: 10.1016/0140-6736(92)91828-v.
16. Pokan R., Hofmann P., von Duvillard S.P. et al. (2006) Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br. J. Sports Med., 40: 773–778. doi: 10.1136/bjsm.2006.027250.
17. Mathers T.W., Beckstrand R.L. (2009) Oral magnesium supplementation in adults with coronary heart disease or coronary heart disease risk. J. Am. Acad. Nurse Pract., 21: 651–657. doi: 10.1111/j.1745-7599.2009.00460.x.
18. Larsson S.C., Orsini N., Wolk A. (2012) Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am. J. Clin. Nutr., 95(2): 362–366. doi: 10.3945/ajcn.111.022376.
19. Hruby A., O’Donnell C. J., Jacques P. F. et al. (2014). Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC: Cardiovascular Imaging, 7(1): 59–69.